-
1 Comment
From a valuation standpoint, the stock is 25.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 997.4.
Based on the above factors, BioAtla, Inc gets an overall score of 1/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US09077B1044 |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | None |
|---|---|
| Market Cap | 27M |
| Target Price | 8.3333 |
| Beta | 0.91 |
| Dividend Yield | None |
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BCAB using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
